KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR

Pinheiro, Manuela; Peixoto, Ana; Rocha, Patrícia; Veiga, Isabel; Pinto, Carla; Santos, Catarina; Pinto, Pedro; Guerra, Joana; Escudeiro, Carla; Barbosa, Alexandra; Silva, João; Teixeira, Manuel R.

doi:10.1007/s00384-022-04126-6

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concordance between tumor tissue and ctDNA analyses using the OncoBEAM and Idylla assays was 83% and 78.7%, respectively, which was improved to 96.2% and 88.5%, respectively, in treatment-naive patients. The authors concluded that analysis of ctDNA is a viable strategy for the clinical management of mCRC patients [ 242 ]. Data are accumulating that ctDNA in CRC patients might be used for surveillance since it detects recurrence 3–11.5 months earlier than imaging.…”

Section: The Cfdna and Ctdna In Cancer Treatmentmentioning

confidence: 99%

The Role of Cell-Free DNA in Cancer Treatment Decision Making

Telekes

Horváth

2022

Cancers

View full text Add to dashboard Cite

The aim of this review is to evaluate the present status of the use of cell-free DNA and its fraction of circulating tumor DNA (ctDNA) because this year July 2022, an ESMO guideline was published regarding the application of ctDNA in patient care. This review is for clinical oncologists to explain the concept, the terms used, the pros and cons of ctDNA; thus, the technical aspects of the different platforms are not reviewed in detail, but we try to help in navigating the current knowledge in liquid biopsy. Since the validated and adequately sensitive ctDNA assays have utility in identifying actionable mutations to direct targeted therapy, ctDNA may be used for this soon in routine clinical practice and in other different areas as well. The cfDNA fragments can be obtained by liquid biopsy and can be used for diagnosis, prognosis, and selecting among treatment options in cancer patients. A great proportion of cfDNA comes from normal cells of the body or from food uptake. Only a small part (<1%) of it is related to tumors, originating from primary tumors, metastatic sites, or circulating tumor cells (CTCs). Soon the data obtained from ctDNA may routinely be used for finding minimal residual disease, detecting relapse, and determining the sites of metastases. It might also be used for deciding appropriate therapy, and/or emerging resistance to the therapy and the data analysis of ctDNA may be combined with imaging or other markers. However, to achieve this goal, further clinical validations are inevitable. As a result, clinicians should be aware of the limitations of the assays. Of course, several open questions are still under research and because of it cfDNA and ctDNA testing are not part of routine care yet.

show abstract

Section: The Cfdna and Ctdna In Cancer Treatmentmentioning

confidence: 99%

The Role of Cell-Free DNA in Cancer Treatment Decision Making

Telekes

Horváth

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Many external stimuli signals, such as enzymatic hydrolysis ( Shen et al, 2013 ; Pinheiro et al, 2022 ; Hack and Bayne, 2022 ), pH response ( Liu H et al, 2013 ), and temperature ( Ke et al, 2015 ), have been used in previous literatures for the release of ctDNA in one piece. It is noteworthy that light has a great advantage over other external stimuli because it is non-contact, accurate, and controllable.…”

Section: Introductionmentioning

confidence: 99%

Near-Infrared Light Regulation of Capture and Release of ctDNA Platforms Based on the DNA Assembly System

Gong

Mao

Wang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Despite recent progress, a challenge remains on how to gently release and recover viable ctDNA captured on DNA probe-based devices. Here, a reusable detector was successfully manufactured for the capture and release of ctDNA by means of an UCNPs@SiO2-Azo/CD-probe. Biocompatible NIR light is used to excite UCNPs and convert into local UV light. Continuous irradiation induces a rapid release of the entire ctDNA-probe–CD complex from the functionalized surface via the trans−cis isomerization of azo units without disrupting the ctDNA-structure receptor. Specifically, these composite chips allow reloading DNA probes for reusable ctDNA detection with no obvious influence on their efficiency. The results of our study demonstrated the potential application of this platform for the quantitative detection of ctDNA and the individualized analysis of cancer patients.

show abstract

Utility of circulating plasma cell-free DNA for detection and quantification of brain arteriovenous malformations

Zhang,

Zhao,

et al. 2024

Nano Today

View full text Add to dashboard Cite

KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR

Cited by 4 publications

References 30 publications

The Role of Cell-Free DNA in Cancer Treatment Decision Making

The Role of Cell-Free DNA in Cancer Treatment Decision Making

Near-Infrared Light Regulation of Capture and Release of ctDNA Platforms Based on the DNA Assembly System

Utility of circulating plasma cell-free DNA for detection and quantification of brain arteriovenous malformations

Contact Info

Product

Resources

About